



NYRx Medicaid Providers Dispense Brand Name Drug when Less Expensive than Generic Program

Effective **7/13/2023**, the following changes will be made to the Dispense Brand Name Drug When Less Expensive Than the Generic Program:

- **Dexilant, Oseni, Protonix suspension, Pylera, Vascepa and Viibryd** will be **ADDED** to the program

In conformance with State Education Law, which intends patients receive the lower cost drug alternative, brand name drugs included in this program:

- **Do Not require "Dispense as Written" (DAW) or "Brand Medically Necessary" on the prescription.**
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

IMPORTANT BILLING INFORMATION

Pursuant to this program, prescription claims submitted to the Medicaid program **do not require** the submission of Dispense as Written/Product Selection Code of '1'; **Pharmacies should submit DAW code 9** (Substitution Allowed by Prescriber but Plan Requests Brand). Pharmacies will receive a NCPDP reject response of "22" which means missing/invalid DAW code if other DAW codes are submitted. The only exception to this, is DAW code 1 and "*Brand Medically Necessary*" on the prescription.

List of Brand Name Drugs included in this program (updated 6/28/2023)

Advair Diskus	Epipen, Epipen JR	Protonix suspension
Alphagan P 0.15%	Firvanq	Pylera
Amitiza	Flovent HFA	Rapamune solution
Apriso	Glumetza	Renvela tablet
Azopt	Hetlioz	Restasis
Bethkis	Kazano	Retin-A cream
Cellcept suspension	Kitabis Pak	Symbicort
Ciprodex	Lialda	Tegretol suspension
Combigan	Nesina	Tegretol XR
Concerta	Nexavar	Trileptal suspension

Copaxone 20mg	Nuvaring	Vascepa
Daytrana	Oseni	Ventolin HFA
Depakote Sprinkle	Pentasa	Viibryd
Dexilant	Pradaxa	Zegerid

Drugs in this program may be subject to prior authorization requirements of other pharmacy programs. This list is subject to change.

If you are having problems viewing content within this newsletter, please email emednyalert@gdit.com for further assistance

The Department has attempted to ensure that the information contained in these notifications is as accurate as possible. However, no e-mail transmittals or materials provided are intended to constitute legal or medical advice.